DongKook Pharmaceutical동국제약
086450 · KOSDAQ · ₩086450 · 동국제약
₩23,900▼ ₩150 (0.62%)End-of-day · Oct 29, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩927B | ₩812B | ₩731B | ₩662B | ₩594B |
| Cost of sales | ₩425B | ₩364B | ₩320B | ₩282B | ₩244B |
| Gross profit | ₩502B | ₩448B | ₩411B | ₩380B | ₩350B |
| Operating income | ₩97B | ₩80B | ₩67B | ₩73B | ₩63B |
| Net income | ₩74B | ₩62B | ₩49B | ₩55B | ₩53B |
| Net income to shareholders | ₩66B | ₩61B | ₩47B | ₩53B | ₩50B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩1.1T | ₩953B | ₩840B | ₩768B | ₩750B |
| Current assets | ₩565B | ₩470B | ₩419B | ₩385B | ₩420B |
| Cash and equivalents | ₩56B | ₩50B | ₩61B | ₩74B | ₩85B |
| Total liabilities | ₩299B | ₩274B | ₩263B | ₩237B | ₩268B |
| Current liabilities | ₩267B | ₩233B | ₩231B | ₩199B | ₩243B |
| Borrowings | ₩1B | ₩848M | ₩77B | ₩66B | ₩98B |
| Total equity | ₩764B | ₩679B | ₩576B | ₩531B | ₩482B |
| Shareholders' equity | ₩664B | ₩603B | ₩545B | ₩502B | ₩455B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩69B | ₩76B | ₩42B | ₩41B | ₩45B |
| Capital spending | ₩43B | ₩27B | ₩34B | ₩47B | ₩51B |
| Free cash flow | ₩26B | ₩50B | ₩7.9B | −₩6.3B | −₩6.4B |
| Dividends paid | ₩9.2B | ₩8.3B | ₩8.1B | ₩8B | ₩8B |
Consolidated where available. Amounts in won.
Also known as: DongKook Pharmaceutical / 동국제약 / 086450 / KRX:086450
Source: KRX statistical information